8^th World Congress on Virology November 28-29, 2016 San Antonio,USA

C. Yong Kang has completed his PhD from McMaster University in Canada and post-doctoral training at the University of Wisconsin-Madison. He served as a Professor of Virology at the University of Texas Southwestern Medical School, Professor and Chairman at the University of Ottawa Faculty of Medicine, and Dean of Science at the University of Western Ontario. He has published 137 peer reviewed research papers and 151 scientific proceedings and abstracts. He holds nine international biotechnology patents. He received numerous awards including the Ho-Am Prize in Medicine. He is a Life-time Fellow of the Royal Society of Canada Academy of Science. He serves as a reviewer for eight international journals.

His research in molecular virology includes the development of viral-specific antiviral therapeutic agents and efficacious vaccines against various human viral diseases including AIDS, hepatitis and hemorrhagic fever with renal syndrome.

DC Tang is the Founder of VaxDome LLC and Vaxin Inc. He was a pioneer during the development of DNA vaccines, noninvasive skin-patch vaccines, adenovirus-vectored vaccines, and the protective innate-adaptive immunity duo platform technology. He was selected as a Distinguished Overseas Scientist by the South Korea KOFST Brain Pool Program; subsequently joined Chung-Ang University and International Vaccine Institute in Seoul; and was appointed as a Scientist at IVI after the Brain Pool Program Award expired in 2013. He founded VaxDome LLC in Birmingham, Alabama, USA in 2014 and moved the company to Dallas, Texas, USA in 2015.

DNA vaccines, noninvasive skin-patch vaccines, adenovirus-vectored vaccines, and the protective innate-adaptive immunity duo platform technology

Professor Ting-Chao Chou received MS degree in Pharmacology from National Taiwan University College of Medicine; Ph.D. from Yale University, and Postdoctoral Fellowship at Johns Hopkins University School of Medicine. Joined Memorial Sloan-Kettering Cancer Center (MSKCC), became Member 1988-96, and a Professor of Pharmacology at Cornell University Graduate School of Medical Sciences, 1988-2000. He is Honorary Professor at Chinese Academy of Medical Sciences, Beijing and five other universities. He focused in the new drug discovery as the Director of Preclinical Pharmacology Core at MSKCC, where he retired on June1, 2013. His 273 scientific articles have been cited by 15,606 papers (as of 8.31.2014). (Thomson Reuters Web of Science: www.researcherid.com/rid/B-4111-2009). Prof. Chou introduced the “Unified Theory of the Median-Effect Equation of the Mass-Action Law”, and with Prof. Paul Talalay (JHU) in 1984, created the “Combination Index Theorem” for multiple entity dynamics. For one article alone (Chou TC and Talalay P., Adv Enz Regul 22:27-55, 1984), cited by 3,218 articles published in 599 biomedical journals and has become one of four the most broadly cited theoretical articles by journals of all time. Chou's dynamics equations and theory has been extended to illustrate the ancient Chinese philosophy and to advocate Econo-Green Bio-Research. He is Inventor/Co-inventor of 36 U.S. Patents, on Editorial Board of five international scientific journals, and is the founder of PD Science, LLC.

Virology

Ronald Moss, M.D. has served as the Chief Executive Officer of Ansun Biopharma, Inc. since October 2012, and before that, served as both interim CEO and Executive Vice President of Clinical Development and Medical Affairs at Ansun from 2008 to 2012. Dr. Moss has held various executive positions in the pharmaceutical industry for over 20 years and has played a pivotal role in successfully leading companies through the complexities of drug and vaccine development. Dr. Moss has been involved in drug and vaccine development of products in Infectious Disease, Allergy, Neurology, Dermatology, Oncology, Respiratory, Transplant, and Autoimmunity in both large pharmaceutical and biotechnology companies, including roles at Aventis, Immune Response, Merck, Telos and Vical. He has also authored over 70 scientific publications. Prior to joining industry, he received his M.D. degree from Chicago Medical School, completed a residency in pediatrics at SUNY Stony Brook and completed a fellowship at the National Institutes of Health. He is double boarded in Pediatrics and Allergy and Immunology. He is also a Fellow of the American Academy and American College of Allergy and Immunology

Infectious Disease, Allergy, Neurology, Dermatology, Oncology, Respiratory, Transplant, and Autoimmunity.

Since 2005 - a CSO at XENOTOX, Inc. Have a medical background (M.D., 1970), Ph.D. in Biochemistry (1973), D.Sc. in Molecular Toxicology (1983). Hold progressively responsible positions: Group Leader (74-79), Head of the Laboratory (1979-87), Department Chair (1987-91), all at Russian Academy of Science. In the US: a Senior Scientist at NCI, NIH (1991-95), Professor (since 2010 - visiting) at Mount Sinai School of Medicine (1995-to date). Author of 5 monographs and 250+ peer reviewed publications. By using enzyme-kinetic and inhibitory analyses, pioneered in revealing TCDD-induced CYP1B1 (FEBS Letters, 1987). Invented the recombinant and TCDD-induced microsomal and isolated monooxygenase isoforms CYP1A1 and CYP1A2, to study regulatory effects of bioflavonoids on procarcinogens metabolism in humans (BBA, 1994). Since the discovery of trans-activation effect of TCDD on HIV-1 (BBRC, 1991), have established Xenobiotical Virology, a biomedical discipline dealing with mechanisms of dioxin effects on DRE-containing genes of human viruses, transcription factors and cytokines linked to inflammation and malignancy pathways.

Viruses

Sita Awasthi has received her Ph.D in Biochemistry from Devi Ahilya University at Indore, India and her postdoctoral training from University of Pennsylvania at Philadelphia. Currently she is a Research Assistant Professor at University of Pennsylvania, Pearlman School of Medicine, Infectious Disease Division. Her research interests are HSV-2 vaccine development against genital herpes disease and HSV-2 HIV-2 co-infections. She has published numerous research articles and serving as an editorial board member of Journals of antivirals and anti retrovirals, Journal of Immunoassay and Immunochemistry.

HIV and Different Viruses

Walter Doerfler has completed Munich Medical School (LMU), Doctor of Medicine thesis in Anatomy and Internships in Munich and Trenton, NJ, USA. He did his Postdoctoral studies in Molecular Genetics at the Max-Planck-Institute for Biochemistry in Munich and in the Department of Biochemistry, Stanford University Medical School.

Genetics and Molecular Virology

Zhanglei has completed her PhD at the age of 30 years from Heping Campus Jilin University. Now she is a associate professor and postgraduate tutor of institute of Special Wild Economic Animals and Plants, Chinese Academy of Agricultural Sciences. Mainly engaged in fur animal disease including molecular epidemiological investigation and diagnosis products research work

Mainly engaged in fur animal disease including molecular epidemiological investigation and diagnosis products research work

Marcin Sieńczyk graduated from the Molecular Biotechnology and Biocatalysis program in 2002 at Wroclaw University of Technology, four years later he obtained his PhD in Medicinal Chemistry. In 2015 he was awarded habilitation (DSc) in Biotechnology. He currently holds the position of assistant professor at Wroclaw University of Technology, Division of Medicinal Chemistry and Microbiology. His research is focused on the development of low molecular weight compounds designed to target proteases involved in the pathogenesis of various diseases including cancer, bacterial and viral infections. Work in his laboratory also generates antibodies to be used in the development of new diagnostic assays for human diseases. He is a co-author of more than 40 papers, 14 patents and more than 25 pending patent applications.

Viruses

Dr.Zenab Torky is an Assistant Professor of Microbiology in the department of Microbiology, Faculty of Science, Ain Shams University, in Egypt. She also worked as a Visiting Scientist in the department of Biological Sciences, University of Louisville, USA. Dr.Zenab has also reviewed and edited many papers for the Food Safety Journal, and participated in two projects with members of the Remold laboratory in University of Louisville, to study the nature and conditions of adaptations of vesicular somatitis virus to a cancer cell line, using molecular biology techniques like genome sequencing and phenotypic characterization of recombinant viruses, to design oncolytic viruses that kill cancer cells, and sampling, genotypic and phenotypic characterization of Pseudomonas bacteria species isolated from human homes, and their pets.

Dr.Zenab’s main research interest is finding a way to protect living cells from viral infection, by studying ways to strengthen the immunity of the host by using natural compounds like antivirals, and studying their effect on viral replication.

Girish J. Kotwal, received his Ph.D. from the Biochemistry department, McMaster University, Canada in 1985. He did his post doctoral work at the National Institutes of Health (NIH) in Bethesda, MD, USA in the Laboratory of Viral Diseases from 1984-1990 and co-discovered the vaccinia virus complement control protein (VCP) along with Dr. Bernard Moss, member of the US National Academy of Science (NAS). During the 90s he established a structural biology program which included overexpression of VCP, a heavily disulphide bonded protein and directed the preclinical program to evaluate the therapeutic potential of VCP. In 2002 he founded Kotwal Bioconsulting, LLC, in 2004 he founded kbiotech pvt. ltd., in South Africa, in 2005 he co-founded InFlaMed Inc. in USA. In 2010 he assisted in founding Icelandic Cardio Pharma (IceCP) in Iceland. He is currently Professor of Biochemistry and Microbiology at UMHS, WI, Adjunct Professor of Medicine, UMass medical school, Worcester, MA and Adjunct Professor of Traditional Chinese Medicine at Henan University, China. He has authored over 100 publications, 97 of which are found on pubmed.

Medical Microbiology, Dental Microbiology and Immunology, Cellular and Molecular Immunology, Intracellular signaling mechanisms in lymphoid cell activation, Cytolytic mechanisms of CTLs and NK cells, Complement pathways & complement regulatory proteins, Immune responses against tumors, Mechanisms of apoptosis in the immune system, transgenic and knockout mice, Modern vaccine design & immunization, HLA & TCR genes in autoimmunity, cellular and molecular mechanisms of autoimmunity, Fundamental Virology, Molecular Virology,

Dominic Targema Abaver has completed his Ph.D.at the age of 40 years from University of Abuja in parasitology; He is chief superintendent of Immigration Nigerian Immigration service, a paramilitary organization in the ministry of interior. He has published number of papers on HIV/AIDS, Immunology and parasitology in reputed journals, such as African Health Science, Pakistani Journal of Medical sciences, African Journal for Physical, Health Education, Recreation and Dance (AJPHERD). He is a member of Nigerian society of parasitology and a fellow, Institute of Cooperate Administration. Currently, D.T. Abaver is a Contract Researcher at Walter Sisulu University, Eastern Cape, South Africa. His research interest include Epidemiology of HIV/AIDS and other Opportunistic Infections; Preventive measures/techniques of HIV/AIDS; gender, age and sexual orientation as determinants for the impact of HIV/AIDS

HIV/Aids

Dr Benani is a responsible of Molecular Biology Laboratory at Pasteur Institute of Morocco this laboratory is a national reference laboratory for Hepatitis C Program (Moroccan ministry of health). He is also the elect-president of Arab Society for Virology and Active member on the Advisory Board, Consultative Meeting on Regional Strategy for Prevention and Control of Viral Hepatitis and Other Epidemics-Prone Blood-Borne Diseases, in 2008 (WHO/EMRO, Cairo, Egypt). He got his master of molecular biology and biotechnology at Université Libre of Bruxelles (ULB, Belgium) and his PhD in molecular microbiology in Fes University (Morocco). He participates in several international and national workshops and congresses. He is also implicated in student’s research for their training, master, and PhD. He published in several journals including journal of medical virology, BMC public health, Virology Journal, He is an active researcher in molecular epidemiology of HBV and HCV in general population and high Risk groups in Morocco. He organized the 1st International Symposium for Virology in Morocco in 2003 (Marrakech, Morocco) and the First PCR Forum and Molecular Typing at Pasteur Institute of Morocco

Molecular epidemiology of HBV and HCV

Dharam V. Ablashi is a microbiologist. He has published over 300 articles on herpesviruses and HIV. His major interests are assessing pathogenic roles of viruses in diseases, and in developing antivirals as therapeutic reagents. He has a BSc, and a D.M.V from Panjab University India, a Dip. Bact from I.V.R.I, and MS in Virology from the University of R.I., USA. He worked 23 years at NIH. In 1986, he co-discovered human herpesvirus-6 (HHV-6), a highly neurotropic and immune suppressive virus. He was as an adjunct professor at Georgetown University School of Medicine, Washington, DC, and Director of Herpesvirus Research in a diagnostic company. Currently, the Scientific Director of the HHV-6 Foundation, and the Senior Technology Adviser at KHG fiteBac Technology in Marietta, Georgia.

Research on herpesviruses and HIV.